Two doses of Pfizer / BioNTech or AstraZeneca / Oxford vaccines protect over 90% of hospitalizations after contracting the delta variant of the coronavirus, which originally appeared in India, according to a study published Monday by British health authorities.
• Read also: LIVE | Latest coronavirus developments
• Read also: Removal of recent restrictions pushed back by a month in the United Kingdom
A Public Health England (PHE) study shows 96% protection against hospitalizations after two doses of Pfizer / BioNTech vaccine and 92% for Oxford / AstraZeneca.
Of the 14,019 people who contracted this variant, only 166 were hospitalized, a study conducted from April 12 to June 4 shows, and emphasizes that these are “results comparable to the effectiveness of the vaccine to prevent hospitalization associated with the alpha variant” that appeared at the end of 2020 in the south east of England.
“This proof of the effectiveness of two doses against variants shows how important revaccination is,” Health Secretary Matt Hancock said, welcoming that the UK vaccination program “has already“ saved thousands of lives ”.
Previous PHE analysis showed that two doses of the vaccine protected the Delta variant as effectively as Alpha, but not a single dose.
For Mary Ramsay, who is in charge of the PHE vaccination, “it is absolutely imperative that both doses be obtained as soon as they are offered, in order to obtain maximum protection against all existing and new options.”
More contagious than the Alpha variant, the Delta variant now dominates the United Kingdom, the country hardest hit by the pandemic in Europe, where nearly 128,000 people have died.
Currently, nearly 80% of adults have received one dose of the vaccine in the UK, but only 57% have received two doses.